BW-180C
Based on 1 publication(s) in Google Scholar
BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 63631-40-3
- Formula: C29H39N5O7
- Molecular Weight:569.65
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) BW-180C
MoreAll Opioid Receptor Isoforms
More
Biological Activity
Opioid Receptor[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
1.3 μM
Compound: DADLE
|
Agonist activity at GFP-fused mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay
Agonist activity at GFP-fused mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay
|
[PMID: 24613457] |
| HEK293 | EC50 |
54 nM
Compound: DADLE
|
Agonist activity at GFP-fused delta opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay
Agonist activity at GFP-fused delta opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay
|
[PMID: 24613457] |
"Pretreatment with BW-180C (DADLE) dose-dependently enhances survival of neurons in the central nervous system. BW-180C is able to induce a reversible hibernation-like state in HeLa cells, a cell line derived from cervical cancer cells, by inhibiting transcription and proliferation in these cells[1].
BW-180C (100 pM to 10 μM) inhibits cellular transcription by ~50% by 24 h compared with vehicle-treated controls[1].
BW-180C does not affect total RNA polymerase II expression. DADLE inhibits phosphorylation of RNA polymerase II in primary cortical neurons[1]. "
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human neuroblastoma cells, SH-SY5Y cells
-
Concentration:100 pM to 10 μM
-
Incubation Time:24-72 hours
-
Result:Significantly inhibited cellular transcription.
-
Cell Line:Primary cortical neurons
-
Concentration:100 nM
-
Incubation Time:72 hours
-
Result:Treatment significantly decreased phosphorylation of RNA polymerase II at both Ser 2 and Ser 5.
BW-180C (DADLE) improves hepatic ischemia/reperfusion injury in mice via activation of the Nrf2/HO1 pathway[3].
DADLE (5 mg/kg) significantly reduces the levels of alanine aminotransferase and aspartate aminotransferase in the serum, and the levels of malondialdehyde in the liver homogenate[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats weighing 200 to 250 g[2]
-
Dosage:5 mg/kg
-
Administration:Administered intravenously into the inferior vena cava
-
Result:After 120 min of reperfusion, the serum GPT levels were significantly lower in the DADLE group than in the Control group.
-
Animal Model:Male C57BL/6 mice (age, 35-42 days; weight, 18-22 g; 6 mice in each group)[3]
-
Dosage:5 mg/kg
-
Administration:Injected intraperitoneally 15 min prior to I/R
-
Result:The serum levels of AST and ALT in the serum DADLE group were significantly lower.
Chemical Information
-
CAS No. 63631-40-3
-
Appearance Solid
-
Molecular Weight 569.65
-
Formula C29H39N5O7
-
Color White to off-white
-
Synonyms
[D-Ala2, D-Leu5]-Enkephalin; DADLE
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Evid Based Complement Alternat Med
δ-Opioid Receptor Activation Inhibits Ferroptosis by Activating the Nrf2 Pathway in MPTP-Induced Parkinson Disease Models. [Abstract]2023 Feb 10:2023:4130937. PMID: 36818224
Solvent & Solubility
DMSO : 250 mg/mL (438.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jie Tian, et al. [D-Ala2, D-Leu5] encephalin (DADLE) reversibly inhibits cellular transcription in neurons without causing cell injury. Brain Res. 2014 May 27;1565:1-7. [Content Brief]
[2]. Kousyou Yamanouchi, et al. [D-Ala2, D-Leu5] enkephalin (DADLE) protects liver against ischemia-reperfusion injury in the rat. J Surg Res. 2003 Sep;114(1):72-7. [Content Brief]
[3]. Zhou Y, et al. DADLE improves hepatic ischemia/reperfusion injury in mice via activation of the Nrf2/HO‑1 pathway. Mol Med Rep. 2017 Nov;16(5):6214-6221. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7555 mL | 8.7773 mL | 17.5546 mL | 43.8866 mL |
| 5 mM | 0.3511 mL | 1.7555 mL | 3.5109 mL | 8.7773 mL | |
| 10 mM | 0.1755 mL | 0.8777 mL | 1.7555 mL | 4.3887 mL | |
| 15 mM | 0.1170 mL | 0.5852 mL | 1.1703 mL | 2.9258 mL | |
| 20 mM | 0.0878 mL | 0.4389 mL | 0.8777 mL | 2.1943 mL | |
| 25 mM | 0.0702 mL | 0.3511 mL | 0.7022 mL | 1.7555 mL | |
| 30 mM | 0.0585 mL | 0.2926 mL | 0.5852 mL | 1.4629 mL | |
| 40 mM | 0.0439 mL | 0.2194 mL | 0.4389 mL | 1.0972 mL | |
| 50 mM | 0.0351 mL | 0.1755 mL | 0.3511 mL | 0.8777 mL | |
| 60 mM | 0.0293 mL | 0.1463 mL | 0.2926 mL | 0.7314 mL | |
| 80 mM | 0.0219 mL | 0.1097 mL | 0.2194 mL | 0.5486 mL | |
| 100 mM | 0.0176 mL | 0.0878 mL | 0.1755 mL | 0.4389 mL |